Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Dr-reddy
DIVA-35 (tablets) SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): DIVA-35 (tablets) COMPOSITION: The 28-day pack (every day pack) contains 21 hormonal tablets each with 2 milligrams cyproterone acetate and 35 micrograms of ethinylestradiol . It also contains 7 non-hormonal tablets PHARMACOLOGICAL CLASSIFICATION: A 21.8.2 Progesterone with estrogens. PHARMACOLOGICAL ACTION: Cyproterone acetate blocks the effect of endogenously produced and exogenously administered androgens at the target organs by means of competitive inhibition. The stimulating effect of male sex hormones on androgen-dependent structures and functions is weakened or abolished by cyproterone acetate. Excessive sebaceous gland function is decreased. Apart from the described anti-androgen effect, cyproterone acetate also has a progestational action. The ethinylestradiol in the combination inhibits ovulation and changes the cervical mucus and the endometrium rendering them unfavourable for sperm penetration and nidation of a fertilized ovum, respectively. INDICATIONS: Androgen-dependent acne, especially those forms which are accompanied by seborrhea or by inflammation or formation of nodes (acne papulopustulosa, acne nodulocystica), androgen-dependent alopecia and mild forms of hirsutism. Oral contraception in women requiring anti-androgen therapy. CONTRA-INDICATIONS: 1. Pregnancy and lactation. 2. Severe disturbances of liver function; recurrent cholestatic jaundice; jaundice or persistent itching during a previous pregnancy; the Dubin-Johnson or Rotor syndromes; previous or existing liver tumours. 3. Existing or previous arterial or venous thrombotic or embolic processes, conditions which predispose to them (e.g. disorders of the clotting system with a tendency towards thrombosis and certain heart diseases). 4. Sickle- Read the complete document